Lumexa Imaging (NASDAQ:LMRI – Get Free Report) had its price target upped by equities research analysts at Wells Fargo & Company from $19.00 to $21.00 in a report issued on Wednesday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective indicates a potential upside of 45.21% from the stock’s current price.
Other equities research analysts also recently issued reports about the stock. Deutsche Bank set a $16.00 price objective on shares of Lumexa Imaging in a research note on Thursday, August 13th. KeyCorp assumed coverage on shares of Lumexa Imaging in a research note on Thursday, September 24th. They issued an “overweight” rating and a $18.00 target price for the company. Wall Street Zen upgraded shares of Lumexa Imaging from a “hold” rating to a “buy” rating in a research report on Saturday, October 3rd. Raymond James Financial set a $19.00 price objective on Lumexa Imaging and gave the company a “strong-buy” rating in a report on Wednesday, November 11th. Finally, Barclays upped their price objective on shares of Lumexa Imaging from $13.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $18.17.
View Our Latest Stock Report on LMRI
Lumexa Imaging Stock Performance
Lumexa Imaging (NASDAQ:LMRI – Get Free Report) last issued its quarterly earnings data on Tuesday, November 10th. The company reported $0.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.07 by $0.19. The business had revenue of $271.97 million for the quarter. Lumexa Imaging had a negative net margin of 1.96% and a negative return on equity of 2.89%. Analysts forecast that Lumexa Imaging will post 0.27 EPS for the current year.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the stock. Aquatic Capital Management LLC purchased a new stake in Lumexa Imaging during the 3rd quarter worth about $77,000. Beck Mack & Oliver LLC raised its stake in Lumexa Imaging by 61.1% in the 3rd quarter. Beck Mack & Oliver LLC now owns 275,075 shares of the company’s stock valued at $2,820,000 after purchasing an additional 104,375 shares during the last quarter. Pathstone Holdings LLC purchased a new stake in Lumexa Imaging in the 3rd quarter valued at about $193,000. First Eagle Investment Management LLC purchased a new stake in Lumexa Imaging during the third quarter valued at about $4,753,000. Finally, Royce & Associates LP boosted its position in Lumexa Imaging by 25.3% during the 3rd quarter. Royce & Associates LP now owns 988,517 shares of the company’s stock worth $10,132,000 after purchasing an additional 199,477 shares during the period.
Lumexa Imaging Company Profile
Lumexa Imaging operates outpatient diagnostic imaging centers that provide radiology services to patients, referring physicians and healthcare providers. Its services include imaging used to help diagnose and monitor a range of medical conditions. The company offers diagnostic procedures such as MRI, CT, PET/CT, mammography, ultrasound and X-ray through its imaging centers and affiliated radiology practices. Lumexa serves communities across the United States, providing an outpatient option for medical imaging outside of a hospital setting.
Featured Articles
- Five stocks we like better than Lumexa Imaging
- SpaceX’s Historic Starship Catch Raises a Bigger Question About Its AI Spending
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
Receive News & Ratings for Lumexa Imaging Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lumexa Imaging and related companies with MarketBeat.com's FREE daily email newsletter.
